I am currently a Senior Scientist with the Enabling Technology
Division of Global Drug Metabolism at Pharmacia Corporation
in Kalamazoo Michigan.
Since
receiving my Ph.D. in 1991 under the direction of Dr. Jim
Halpert,
I have spent the past 10 years in the pharmaceutical
industry. After completing a postdoctoral scientist position
at Eli Lilly in 1992, I worked for 7 years at Rhône-Poulenc
Rorer (currently Aventis) in the Drug Metabolism and Pharmacokinetics
department.
Since joining Pharmacia in 1999, one of my primary responsibilities
has been as a project team representative for an infectious
disease program. This involves providing metabolism support
and interacting with various disciplines involved in the
discovery and development process (medicinal chemistry, pharmacology,
pharmaceutics, clinical, etc.).
In addition, my group is involved in technology development
and implementation. These projects have included the characterization
of species differences in metabolic capabilities, the role
of glucuronidation in drug clearance, and in silico approaches
to predictive drug metabolism.
The toxicology training program at Arizona has provided
a strong foundation for my career in three critical areas;
mechanisms and results of toxicology from a multidisciplinary
perspective, the emphasis on clear scientific approach and
experimental design, and written and verbal presentation
of results.
Specifically, my graduate work in characterization of animal
cytochrome P450 forms and in vitro metabolism provided an
easy transition to in vitro approaches to drug metabolism
and predictions of drug interactions within the pharmaceutical
industry.
Finally, my interactions with several members of the department
have continued to include scientific collaborations and interactions
within professional societies and journals.
|
